Today: August 28, 2015, 9:16 pm

SADIF Analytics releases new summary due diligence report for Exalenz Bioscience Ltd. (EXEN)

SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Exalenz Bioscience Ltd. (EXEN) and produced a report, rating the company's attractiveness to long-term investors. 2014-04-18 14:24:48
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Exalenz Bioscience Ltd. (EXEN). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Exalenz Bioscience Ltd. investor.

Report Summary: Exalenz Bioscience Ltd. is an average quality company with a positive outlook. Exalenz Bioscience Ltd. has strong business growth and is run by inefficient management. The trend in Exalenz Bioscience Ltd. fair value exchange rate against its closest rated-competitor, Given Imaging Ltd. (Israel), has been stable over the past 2 weeks. When compared to its closest competitor, Exalenz Bioscience Ltd. shows similar undervaluation and is equally likely to underperform the market.

The report breaks down the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Exalenz Bioscience Ltd. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext and from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, One source West Services, and Dow Jones/Factiva.

About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering 31 different markets and over 22,000 companies. The StockMarks rating system is based on proven investment principles and is designed to drive long-term shareholder returns.

Press Information
SADIF - Investment Analytics
SADIF - Investment Analytics
Rua Domingos F. Pinto Basto, 21
3830-176 Ilhavo, Portugal

António Mendes
(+351) 234 296930

Published by
Antonio Mendes
(+351) 234 322 037
Related Articles

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.